A Phase I Study to Investigate the Effect of Hepatic Impairm... | Clinical Trial | StuddyBuddy@endsection A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234
Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Recruiting NCT07546760

A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234

Conditions: Hepatic Impairment

Sex: All
Ages: 18 Years – 85 Years
Healthy volunteers: Yes
Phase: PHASE1
Enrollment: 28
Sponsor: AstraZeneca

Location: Research Site Chandler Arizona

Summary

The purpose of this study is to examine the safety and tolerability of AZD6234 and AZD9550 in participants with hepatic impairment and participants with normal hepatic function.

Eligibility Criteria

Inclusion Criteria 1. Age 18-85 years at consent. 2. Groups: * Healthy controls: Medically healthy; no clinically significant findings in history, exam, labs, vitals, or 12 lead ECG (per investigator). * Hepatic impairment: Chronic (≥6 months), stable; documented Child Pugh B (Group 2) or C (Group 1). 3. Stable concomitant regimen ≥2 weeks before screening (Groups 1-2). 4. T2DM allowed if HbA1c \1.5×ULN; ii) WBC/platelets \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07546760). StuddyBuddy aggregates publicly available trial information.